Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs)

Drug Discovery Today

Volumn 12, Issue 5-6, 2007, Pages 241-248

  Gao, Wenqing ^a   Dalton, James T ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b GTx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; AROMATASE INHIBITOR; FINASTERIDE; FLUOXYMESTERONE; FLUTAMIDE; HYDANTOIN DERIVATIVE; METHYLTESTOSTERONE; NANDROLONE; OXANDROLONE; QUINOLINE DERIVATIVE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; STEROID; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; TESTOSTERONE ESTER; UNCLASSIFIED DRUG;

ANDROGEN THERAPY; CONTRACEPTION; GENE EXPRESSION REGULATION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LIVER TOXICITY; MUSCLE ATROPHY; OSTEOPOROSIS; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROTEIN INTERACTION; REVIEW; SIDE EFFECT; TISSUE DISTRIBUTION; TISSUE SPECIFICITY;

ANDROGEN ANTAGONISTS; ANDROGENS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; MALE; ORGAN SPECIFICITY; RECEPTORS, ANDROGEN; TISSUE DISTRIBUTION;

EID: 33847184616     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.01.003     Document Type: Review

References (65)

1. Gao W., et al. Chemistry and structural biology of androgen receptor. Chem. Rev. 105 (2005) 3352-3370
2. Fang H., et al. Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem. Res. Toxicol. 16 (2003) 1338-1358
3. Burger A., and Abraham D.J. Burger's Medicinal Chemistry and Drug Discovery (2003), Wiley
4. Bohl C.E., et al. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 6201-6206
5. Matias P.M., et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem. 275 (2000) 26164-26171
6. Colombo D., et al. A comparative molecular modeling study of dydrogesterone with other progestational agents through theoretical calculations and nuclear magnetic resonance spectroscopy. J. Steroid Biochem. Mol. Biol. 98 (2006) 56-62
7. Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J. Clin. Endocrinol. Metab. 84 (1999) 3459-3462
8. Segal S., et al. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opin. Investig. Drugs 15 (2006) 377-387
9. Kawano H., et al. Suppressive function of androgen receptor in bone resorption. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9416-9421
10. Chen J., et al. Discovery and therapeutic promise of selective androgen receptor modulators. Mol. Interv. 5 (2005) 173-188
11. Foye W.O., et al. Foye's Principles of Medicinal Chemistry (2002), Lippincott Williams & Wilkins
12. Wu F.C., and von Eckardstein A. Androgens and coronary artery disease. Endocr. Rev. 24 (2003) 183-217
13. Mooradian A.D., et al. Biological actions of androgens. Endocr. Rev. 8 (1987) 1-28
14. Eckardstein A., and Wu F.C. Testosterone and atherosclerosis. Growth Horm IGF Res 13 Suppl A (2003) S72-S84
15. Chacon A., and Monga M. Medical management of benign prostatic hyperplasia. Geriatr. Nephrol. Urol. 9 (1999) 39-48
16. Radlmaier A., et al. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group. Prostate 29 (1996) 199-208
17. Gingell J.C., et al. Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. The Schering 90.062 Study Group. J. Urol. 154 (1995) 399-401
18. Habenicht U.F., et al. Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors. J. Steroid Biochem. Mol. Biol. 44 (1993) 557-563
19. Keller E.T., et al. The androgen receptor: a mediator of diverse responses. Front. Biosci. 1 (1996) d59-d71
20. Mosselman S., et al. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 392 (1996) 49-53
21. Thigpen A.E., et al. Molecular genetics of steroid 5 alpha-reductase 2 deficiency. J. Clin. Invest. 90 (1992) 799-809
22. Wright A.S., et al. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinology 140 (1999) 4509-4515
23. Oettel M. Testosterone metabolism, dose-response relationships and receptor polymorphisms: selected pharmacological/toxicological considerations on benefits versus risks of testosterone therapy in men. Aging Male 6 (2003) 230-256
24. Russell D.W., et al. The molecular genetics of steroid 5 alpha-reductases. Recent Prog. Horm. Res. 49 (1994) 275-284
25. Oettel M. Is there a role for estrogens in the maintenance of men's health?. Aging Male 5 (2002) 248-257
26. de Ronde W., et al. The importance of oestrogens in males. Clin. Endocrinol. (Oxf.) 58 (2003) 529-542
27. Barrett-Connor E., et al. Endogenous sex hormones and cognitive function in older men. J. Clin. Endocrinol. Metab. 84 (1999) 3681-3685
28. Van Pottelbergh I., et al. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 166 (2003) 95-102
29. Mukherjee T.K., et al. Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 4055-4060
30. Toda K., et al. Oestrogen at the neonatal stage is critical for the reproductive ability of male mice as revealed by supplementation with 17beta-oestradiol to aromatase gene (Cyp19) knockout mice. J. Endocrinol. 168 (2001) 455-463
31. Falahati-Nini A., et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J. Clin. Invest. 106 (2000) 1553-1560
32. Orwoll E.S. Men, bone and estrogen: unresolved issues. Osteoporos. Int. 14 (2003) 93-98
33. Pratt W.B., and Toft D.O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev. 18 (1997) 306-360
34. Heinlein C.A., and Chang C. Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 23 (2002) 175-200
35. Shang Y., et al. Formation of the androgen receptor transcription complex. Mol. Cell 9 (2002) 601-610
36. Lutz L.B., et al. Selective modulation of genomic and nongenomic androgen responses by androgen receptor ligands. Mol. Endocrinol. 17 (2003) 1106-1116
37. Estrada M., et al. Testosterone stimulates intracellular calcium release and mitogen-activated protein kinases via a G protein-coupled receptor in skeletal muscle cells. Endocrinology 144 (2003) 3586-3597
38. Kousteni S., et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104 (2001) 719-730
39. Zagar Y., et al. Signaling cross-talk from Gbeta4 subunit to Elk-1 in the rapid action of androgens. J. Biol. Chem. 279 (2004) 2403-2413
40. Kampa M., et al. The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton. FASEB J. 16 (2002) 1429-1431
41. Unni E., et al. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res. 64 (2004) 7156-7168
42. Norman A.W., et al. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat. Rev. Drug Discov. 3 (2004) 27-41
43. Migliaccio A., et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J. 19 (2000) 5406-5417
44. Sathya G., et al. Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. Cancer Res. 63 (2003) 8029-8036
45. Callewaert L., et al. Interplay between two hormone-independent activation domains in the androgen receptor. Cancer Res. 66 (2006) 543-553
46. Hodgson M.C., et al. The androgen receptor recruits nuclear receptor corepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J. Biol. Chem. 280 (2005) 6511-6519
47. Carlson K.E., and Katzenellenbogen J.A. A comparative study of the selectivity and efficiency of target tissue uptake of five tritium-labeled androgens in the rat. J. Steroid Biochem. 36 (1990) 549-561
48. Parent E.E., et al. Synthesis and biological evaluation of a nonsteroidal bromine-76-labeled androgen receptor ligand 3-[76Br]bromo-hydroxyflutamide. Nucl. Med. Biol. 33 (2006) 705-713
49. Gao W., et al. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology 145 (2004) 5420-5428
50. Bjornstrom L., and Sjoberg M. Estrogen receptor-dependent activation of AP-1 via non-genomic signalling. Nucl. Recept. 2 (2004) 3
51. Kousteni S., et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298 (2002) 843-846
52. Dalton J.T., et al. Discovery of nonsteroidal androgens. Biochem. Biophys. Res. Commun. 244 (1998) 1-4
53. Edwards J.P., et al. New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. Bioorg. Med. Chem. Lett. 8 (1998) 745-750
54. Yin D., et al. Pharmacodynamics of selective androgen receptor modulators. J. Pharmacol. Exp. Ther. 304 (2003) 1334-1340
55. Hanada K., et al. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol. Pharm. Bull. 26 (2003) 1563-1569
56. Miner J.N., et al. An orally-active selective androgen receptor modulator is efficacious on bone, muscle and sex function with reduced impact on prostate. Endocrinology (2006). http://endo.endojournals.org 10.1210/en.2006-0793
57. Cadilla R., and Turnbull P. Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential. Curr. Top. Med. Chem. 6 (2006) 245-270
58. Gao W., et al. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm. Res. 23 (2006) 1641-1658
59. Buijsman R.C., et al. Non-steroidal steroid receptor modulators. Curr. Med. Chem. 12 (2005) 1017-1075
60. Gao W., et al. Selective androgen receptor modulator (SARM) treatment improves muscle strength and body composition, and prevents bone loss in orchidectomized rats. Endocrinology 146 (2005) 4887-4897
61. Chen J., et al. A selective androgen receptor modulator for hormonal male contraception. J. Pharmacol. Exp. Ther. 312 (2005) 546-553
62. Furr B.J., and Tucker H. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 47 Suppl. 1A (1996) 13-25 discussion 29-32
63. Cockshott I.D. Bicalutamide: clinical pharmacokinetics and metabolism. Clin. Pharmacokinet. 43 (2004) 855-878
64. Chang C.Y., et al. Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. Mol. Endocrinol. 19 (2005) 2478-2490
65. Arnold L.A., et al. Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. J. Biol. Chem. 280 (2005) 43048-43055